Report cover image

Global FIC Single-target Drugs Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 202 Pages
SKU # APRC20280239

Description

Summary

According to APO Research, the global FIC Single-target Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for FIC Single-target Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for FIC Single-target Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the FIC Single-target Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for FIC Single-target Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the FIC Single-target Drugs market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Polarean lmaging and Phathom, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for FIC Single-target Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of FIC Single-target Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for FIC Single-target Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the FIC Single-target Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global FIC Single-target Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for FIC Single-target Drugs sales, projected growth trends, production technology, application and end-user industry.

FIC Single-target Drugs Segment by Company

Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Polarean lmaging
Phathom
Marinus
Mallinckrodt
ImmunoGen
Immunocore
Gilead
Genentech
Dermavant Sciences
Boehringer Ingelheim
BMS
Agios
FIC Single-target Drugs Segment by Type

ALK2 Inhibitors
Citron Inhibitors
GCN2 Agonists
RORγ Covalent Inhibitors
Others
FIC Single-target Drugs Segment by Application

Hospital
Clinic
Other
FIC Single-target Drugs Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global FIC Single-target Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions FIC Single-target Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify FIC Single-target Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze FIC Single-target Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Single-target Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of FIC Single-target Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Single-target Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FIC Single-target Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global FIC Single-target Drugs industry.
Chapter 3: Detailed analysis of FIC Single-target Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of FIC Single-target Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of FIC Single-target Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

202 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global FIC Single-target Drugs Sales Value (2020-2031)
1.2.2 Global FIC Single-target Drugs Sales Volume (2020-2031)
1.2.3 Global FIC Single-target Drugs Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 FIC Single-target Drugs Market Dynamics
2.1 FIC Single-target Drugs Industry Trends
2.2 FIC Single-target Drugs Industry Drivers
2.3 FIC Single-target Drugs Industry Opportunities and Challenges
2.4 FIC Single-target Drugs Industry Restraints
3 FIC Single-target Drugs Market by Company
3.1 Global FIC Single-target Drugs Company Revenue Ranking in 2024
3.2 Global FIC Single-target Drugs Revenue by Company (2020-2025)
3.3 Global FIC Single-target Drugs Sales Volume by Company (2020-2025)
3.4 Global FIC Single-target Drugs Average Price by Company (2020-2025)
3.5 Global FIC Single-target Drugs Company Ranking (2023-2025)
3.6 Global FIC Single-target Drugs Company Manufacturing Base and Headquarters
3.7 Global FIC Single-target Drugs Company Product Type and Application
3.8 Global FIC Single-target Drugs Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global FIC Single-target Drugs Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 FIC Single-target Drugs Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 FIC Single-target Drugs Market by Type
4.1 FIC Single-target Drugs Type Introduction
4.1.1 ALK2 Inhibitors
4.1.2 Citron Inhibitors
4.1.3 GCN2 Agonists
4.1.4 RORγ Covalent Inhibitors
4.1.5 Others
4.2 Global FIC Single-target Drugs Sales Volume by Type
4.2.1 Global FIC Single-target Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global FIC Single-target Drugs Sales Volume by Type (2020-2031)
4.2.3 Global FIC Single-target Drugs Sales Volume Share by Type (2020-2031)
4.3 Global FIC Single-target Drugs Sales Value by Type
4.3.1 Global FIC Single-target Drugs Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global FIC Single-target Drugs Sales Value by Type (2020-2031)
4.3.3 Global FIC Single-target Drugs Sales Value Share by Type (2020-2031)
5 FIC Single-target Drugs Market by Application
5.1 FIC Single-target Drugs Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Other
5.2 Global FIC Single-target Drugs Sales Volume by Application
5.2.1 Global FIC Single-target Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global FIC Single-target Drugs Sales Volume by Application (2020-2031)
5.2.3 Global FIC Single-target Drugs Sales Volume Share by Application (2020-2031)
5.3 Global FIC Single-target Drugs Sales Value by Application
5.3.1 Global FIC Single-target Drugs Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global FIC Single-target Drugs Sales Value by Application (2020-2031)
5.3.3 Global FIC Single-target Drugs Sales Value Share by Application (2020-2031)
6 FIC Single-target Drugs Regional Sales and Value Analysis
6.1 Global FIC Single-target Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global FIC Single-target Drugs Sales by Region (2020-2031)
6.2.1 Global FIC Single-target Drugs Sales by Region: 2020-2025
6.2.2 Global FIC Single-target Drugs Sales by Region (2026-2031)
6.3 Global FIC Single-target Drugs Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global FIC Single-target Drugs Sales Value by Region (2020-2031)
6.4.1 Global FIC Single-target Drugs Sales Value by Region: 2020-2025
6.4.2 Global FIC Single-target Drugs Sales Value by Region (2026-2031)
6.5 Global FIC Single-target Drugs Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America FIC Single-target Drugs Sales Value (2020-2031)
6.6.2 North America FIC Single-target Drugs Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe FIC Single-target Drugs Sales Value (2020-2031)
6.7.2 Europe FIC Single-target Drugs Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific FIC Single-target Drugs Sales Value (2020-2031)
6.8.2 Asia-Pacific FIC Single-target Drugs Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America FIC Single-target Drugs Sales Value (2020-2031)
6.9.2 South America FIC Single-target Drugs Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa FIC Single-target Drugs Sales Value (2020-2031)
6.10.2 Middle East & Africa FIC Single-target Drugs Sales Value Share by Country, 2024 VS 2031
7 FIC Single-target Drugs Country-level Sales and Value Analysis
7.1 Global FIC Single-target Drugs Sales by Country: 2020 VS 2024 VS 2031
7.2 Global FIC Single-target Drugs Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global FIC Single-target Drugs Sales by Country (2020-2031)
7.3.1 Global FIC Single-target Drugs Sales by Country (2020-2025)
7.3.2 Global FIC Single-target Drugs Sales by Country (2026-2031)
7.4 Global FIC Single-target Drugs Sales Value by Country (2020-2031)
7.4.1 Global FIC Single-target Drugs Sales Value by Country (2020-2025)
7.4.2 Global FIC Single-target Drugs Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.5.2 USA FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.5.3 USA FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Canada FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Mexico FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.8.2 Germany FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.9.2 France FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.9.3 France FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.10.2 U.K. FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.11.2 Italy FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.12.2 Spain FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.13.2 Russia FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.16.2 China FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.16.3 China FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.17.2 Japan FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.18.2 South Korea FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.19.2 India FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.19.3 India FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.20.2 Australia FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.22.2 Brazil FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.23.2 Argentina FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.24.2 Chile FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.25.2 Colombia FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.26.2 Peru FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.28.2 Israel FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.29.2 UAE FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.30.2 Turkey FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.31.2 Iran FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt FIC Single-target Drugs Sales Value Growth Rate (2020-2031)
7.32.2 Egypt FIC Single-target Drugs Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt FIC Single-target Drugs Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Sanofi
8.1.1 Sanofi Comapny Information
8.1.2 Sanofi Business Overview
8.1.3 Sanofi FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.1.4 Sanofi FIC Single-target Drugs Product Portfolio
8.1.5 Sanofi Recent Developments
8.2 Johnson & Johnson
8.2.1 Johnson & Johnson Comapny Information
8.2.2 Johnson & Johnson Business Overview
8.2.3 Johnson & Johnson FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.2.4 Johnson & Johnson FIC Single-target Drugs Product Portfolio
8.2.5 Johnson & Johnson Recent Developments
8.3 Novartis
8.3.1 Novartis Comapny Information
8.3.2 Novartis Business Overview
8.3.3 Novartis FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.3.4 Novartis FIC Single-target Drugs Product Portfolio
8.3.5 Novartis Recent Developments
8.4 Merck
8.4.1 Merck Comapny Information
8.4.2 Merck Business Overview
8.4.3 Merck FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.4.4 Merck FIC Single-target Drugs Product Portfolio
8.4.5 Merck Recent Developments
8.5 Roche
8.5.1 Roche Comapny Information
8.5.2 Roche Business Overview
8.5.3 Roche FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.5.4 Roche FIC Single-target Drugs Product Portfolio
8.5.5 Roche Recent Developments
8.6 Eli Lilly
8.6.1 Eli Lilly Comapny Information
8.6.2 Eli Lilly Business Overview
8.6.3 Eli Lilly FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.6.4 Eli Lilly FIC Single-target Drugs Product Portfolio
8.6.5 Eli Lilly Recent Developments
8.7 Pfizer
8.7.1 Pfizer Comapny Information
8.7.2 Pfizer Business Overview
8.7.3 Pfizer FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.7.4 Pfizer FIC Single-target Drugs Product Portfolio
8.7.5 Pfizer Recent Developments
8.8 Polarean lmaging
8.8.1 Polarean lmaging Comapny Information
8.8.2 Polarean lmaging Business Overview
8.8.3 Polarean lmaging FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.8.4 Polarean lmaging FIC Single-target Drugs Product Portfolio
8.8.5 Polarean lmaging Recent Developments
8.9 Phathom
8.9.1 Phathom Comapny Information
8.9.2 Phathom Business Overview
8.9.3 Phathom FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.9.4 Phathom FIC Single-target Drugs Product Portfolio
8.9.5 Phathom Recent Developments
8.10 Marinus
8.10.1 Marinus Comapny Information
8.10.2 Marinus Business Overview
8.10.3 Marinus FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.10.4 Marinus FIC Single-target Drugs Product Portfolio
8.10.5 Marinus Recent Developments
8.11 Mallinckrodt
8.11.1 Mallinckrodt Comapny Information
8.11.2 Mallinckrodt Business Overview
8.11.3 Mallinckrodt FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.11.4 Mallinckrodt FIC Single-target Drugs Product Portfolio
8.11.5 Mallinckrodt Recent Developments
8.12 ImmunoGen
8.12.1 ImmunoGen Comapny Information
8.12.2 ImmunoGen Business Overview
8.12.3 ImmunoGen FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.12.4 ImmunoGen FIC Single-target Drugs Product Portfolio
8.12.5 ImmunoGen Recent Developments
8.13 Immunocore
8.13.1 Immunocore Comapny Information
8.13.2 Immunocore Business Overview
8.13.3 Immunocore FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.13.4 Immunocore FIC Single-target Drugs Product Portfolio
8.13.5 Immunocore Recent Developments
8.14 Gilead
8.14.1 Gilead Comapny Information
8.14.2 Gilead Business Overview
8.14.3 Gilead FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.14.4 Gilead FIC Single-target Drugs Product Portfolio
8.14.5 Gilead Recent Developments
8.15 Genentech
8.15.1 Genentech Comapny Information
8.15.2 Genentech Business Overview
8.15.3 Genentech FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.15.4 Genentech FIC Single-target Drugs Product Portfolio
8.15.5 Genentech Recent Developments
8.16 Dermavant Sciences
8.16.1 Dermavant Sciences Comapny Information
8.16.2 Dermavant Sciences Business Overview
8.16.3 Dermavant Sciences FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.16.4 Dermavant Sciences FIC Single-target Drugs Product Portfolio
8.16.5 Dermavant Sciences Recent Developments
8.17 Boehringer Ingelheim
8.17.1 Boehringer Ingelheim Comapny Information
8.17.2 Boehringer Ingelheim Business Overview
8.17.3 Boehringer Ingelheim FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.17.4 Boehringer Ingelheim FIC Single-target Drugs Product Portfolio
8.17.5 Boehringer Ingelheim Recent Developments
8.18 BMS
8.18.1 BMS Comapny Information
8.18.2 BMS Business Overview
8.18.3 BMS FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.18.4 BMS FIC Single-target Drugs Product Portfolio
8.18.5 BMS Recent Developments
8.19 Agios
8.19.1 Agios Comapny Information
8.19.2 Agios Business Overview
8.19.3 Agios FIC Single-target Drugs Sales, Value and Gross Margin (2020-2025)
8.19.4 Agios FIC Single-target Drugs Product Portfolio
8.19.5 Agios Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 FIC Single-target Drugs Value Chain Analysis
9.1.1 FIC Single-target Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 FIC Single-target Drugs Sales Mode & Process
9.2 FIC Single-target Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 FIC Single-target Drugs Distributors
9.2.3 FIC Single-target Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.